Physician profile
Mark Mozingo
NPI 1427077882
$923.30
in general payments reported to CMS, 2019-2025
18 companies · $355 in 2025
The $355 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $260 · 2023: $148 · 2024: $160 · 2025: $355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $663.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $663.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $213.00 | 2022-2025 | |
| Novo Nordisk INC | $169.27 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $149.89 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $58.55 | 2022-2025 | Arexvy, Nucala |
| Exact Sciences Corporation | $45.62 | 2024-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $43.11 | 2022 | |
| Pfizer INC. | $41.87 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.05 | 2023 | |
| Phathom Pharmaceuticals, INC. | $25.41 | 2025 | Voquezna |
| Sumitomo Pharma America, INC. | $24.16 | 2025 | Gemtesa |
| Janssen Biotech, INC. | $22.33 | 2024 | Stelara |
| Sanofi-Aventis U.S. LLC | $18.66 | 2022 | |
| Insmed, INC. | $17.79 | 2024 | Arikayce |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.69 | 2022 | |
| Braintree Laboratories, INC. | $14.75 | 2025 | Suflave, Sutab |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cequr Corporation | $13.26 | 2025 | Cequr Simplicity |
| Axsome Therapeutics, INC. | $13.14 | 2023 | Sunosi |
| Dynavax Technologies Corporation | $6.75 | 2025 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Mozingo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.